Regen BioPharma and researchers have identified three new series of small molecule drugs that inhibit NR2F6, bringing the total number of these series to five.
"Finding potent small molecule inhibitors of NR2F6 is central to our goal of identifying and protecting the intellectual property landscape around this program. Therefore, we continue to screen for NR2F6 inhibitors using a second proprietary assay and have identified three new series of drugs that inhibit NR2F6 in a concentration-dependent manner," said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"As we move some of these molecules forward in our development program, we will submit the appropriate patent filings to continue to add value to the program and Regen shareholders," said David Koos, Ph.D., Chairman & CEO Regen BioPharma.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 small molecule program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.